Академический Документы
Профессиональный Документы
Культура Документы
Oulu, Finland, January 31, 2019 --(PR.com)-- Paras Biopharmaceuticals Finland Oy today announced
the achievement of a major milestone - the successful development of biologically active Romiplostim
(N-Plate® biosimilar) production technology.
Romiplostim has been produced with a proprietary and innovative continuous manufacturing process at
the company's Finnish-based facility in Oulu-Finland. Romiplostim is used for the treatment of
thrombocytopenia (low platelet count) in patients with chronic immune (idiopathic) thrombocytopenic
purpura (ITP).
ITP is a potentially serious blood disorder characterized by increased destruction and impaired production
of platelets. It can lead to extensive bruising and bleeding. Thrombocytopenia is common in cancer
patients, resulting from chemotherapy or radiation treatment, in addition to the underlying disease itself.
ITP leads to several complications. Low platelet count increases spontaneous bleeding, complicates
surgical operations and can affect chemotherapy and radiation therapy.
“The company is evaluating completed batches to assess comparability and looks forward to finalizing
this work in the anticipation of supporting clinical trials & approvals for commercial supply on patent
expiry in Europe and USA,” says Dr Mark Jackson Research & Admin Group, Paras Biopharmaceuticals.
Page 1/3
PR.com Press Release Distribution Terms of Use
Paras Biopharmaceuticals has a fully equipped microbial production facility in Finland for the production
of recombinant therapeutic products. With a total floor area of 25,000 ft2 and a classified cleanroom of
4,300 ft2, other features include media and buffer preparation, live area (fermentation and harvest &
extraction), purification suite (incl. +4°C cold room), final filtration and freeze-drying.
Paras Biopharmaceuticals has developed and is now offering clinical development and marketing
collaboration for the following Biosimilars: Recombinant Teriparatide (Forteo® Biosimilar),
Recombinant Anakinra (Kineret® Biosimilar), Analog Insulin Aspart®, Recombinant Rasburicase
(Elitek® / Fasturtec® Biosimilar) and Recombinant Romiplostim (N-plate® Biosimilar). The company
has achieved efficient and cost-effective production of high value biosimilars. Paras Biopharmaceuticals
has developed a proprietary platform which includes Diabrid® Technology, Noblecleav® Technology
and Biomultifold® Technology.
Page 2/3
PR.com Press Release Distribution Terms of Use
Contact Information:
Paras Biopharmaceuticals Finland Oy
Dr. Mark Jackson
+358442905993
Contact via Email
www.parasbiopharma.com
News Image:
Page 3/3
PR.com Press Release Distribution Terms of Use